TrialJournal of neurology2025

Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study.

Vera Bril et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.